Clinical Trial

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

Study acronym: ANCHOR-POC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times
Protocol Amendment History 4 changes
notable Trial sites expanded: 53 -> 57 locations 2026-07-17
notable Trial sites expanded: 47 -> 51 locations 2026-05-21
notable Trial sites expanded: 39 -> 47 locations 2026-04-29
notable Trial sites expanded: 29 -> 39 locations 2026-04-17
Trial Details
NCT Number NCT07271186
Lead Sponsor Regeneron Pharmaceuticals
Conditions Diabetic Kidney Disease (DKD)
Enrollment 270 participants
Start Date 2026-01-09
Primary Completion 2027-09-24 (estimated)
Study Completion 2028-04-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-10